Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

BACKGROUND: Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV use in hospitalized patients during the EUA period are not well described. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Elshaboury, Ramy H., Monk, Miranda M., Bebell, Lisa M., Bidell, Monique R., Adamsick, Meagan L., Gandhi, Ronak G., Paras, Molly L., Hohmann, Elizabeth L., Letourneau, Alyssa R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474339/
https://www.ncbi.nlm.nih.gov/pubmed/34589214
http://dx.doi.org/10.1177/20499361211046669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474339/
https://www.ncbi.nlm.nih.gov/pubmed/34589214
http://dx.doi.org/10.1177/20499361211046669

Ejemplares similares